Piramal Healthcare Ltd (PHL) has acquired polygeline based blood plasma products brand 'Haemaccel' of PlasmaSelect AG, Germany for a total consideration of Euro 7.7 million (around Rs 52.6 crore). The German company is marketing these products in over 38 countries. This acquisition will give global leadership to PHL's polygeline-based blood plasma expansion products. Currently, PHL is marketing the products under the brand name 'Haamaccel' in India and under the brand name 'Haemagline' in 17 other countries.

The transaction includes the brand rights, contracts, registrations dossiers and know-how relating to Haemaccel and associated brands. It excludes the manufacturing facility of PlasmaSelect at Marburg, Germany. PlasmaSelect will continue to manufacture Haemaccel as per PHLs requirements to facilitate orderly migration of manufacturing to the new facility at Baddi in India.

Commenting on the acquisition, Ajay Piramal, chairman, said, "Over the years, we have recognised the compelling potential of the Global Critical Care business. We aspire to become a leading global player in this business with our worldwide distribution network and state-of-the-art manufacturing facilities in India. This acquisition is a stepping stone in that direction and a reflection of our commitment to knowledge and innovation, dynamic action and care that empowers - consistent with our Group's values."

The total annual revenues of Haemaccel and associated brands of PHL and PlasmaSelect together are estimated Euro 9.1 million, at current exchange rates. Blood plasma expansion products are a part of the Global Critical Care business division of PHL. The Global Critical Care division markets a range of important hospital pharmaceuticals, including Halothane/Isoflurane inhalation anaesthetics. The acquisition is consistent with PHL's objective of growing its global critical care business.

PHL is setting-up a new EDQM and UK MHRA - compliant Haemaccel manufacturing facility at Baddi, India with an initial rated capacity of 4.2 million units. This capacity would be able to service the expanded Haemaccel sales.